Publications by authors named "Suki Leung"
Article Synopsis
- Long-acting injectable cabotegravir + rilpivirine (CAB + RPV LAI) was approved in November 2021 for use in virally suppressed adults in England and Wales, and the evaluation of its delivery processes took place across 12 clinics.* -
- A total of 518 adults were approved for CAB + RPV LAI from February 2022 to December 2023, with 423 receiving at least one injection; the treatment had a median duration of 7.5 months and a high adherence rate of 97% for timely injections.* -
- Results indicated only 0.7% experienced virological failure and 6% discontinued treatment, showcasing that effective clinic protocols and
Background: Doravirine is a non-nucleoside reverse transcriptase inhibitor recommended for the treatment of virologically suppressed and treatment naïve people living with HIV. The DRIVE-REAL study aimed to describe the characteristics, treatment patterns, and virological outcomes of doravirine users in a real-world cohort in the UK.
Methods: A retrospective, observational, multi-centre chart review was conducted for 300 adults living with HIV initiating doravirine-containing antiretroviral therapy.
We report the first published case of a drug induced liver injury (DILI) presumed secondary to a drug-drug interaction between ritonavir and levonorgestrel progestogen-only emergency contraception (POEC). Our patient is a 25-year-old female living with human immunodeficiency virus (HIV), taking antiretroviral therapy (ART) containing tenofovir alafenamide/emtricitabine and darunavir/ritonavir. She was found to have elevated transaminases at a routine clinic appointment consistent with hepatocellular DILI.
View Article and Find Full Text PDF